whytestbanner_desktop whytestbanner_mobile

Why test PD-L1?

Potential use of biomarkers in oncology

Biomarkers have many potential applications in oncology, including risk assessment, screening, differential diagnosis, determination of prognosis, prediction of response to treatment, and monitoring of disease progression.1

potential users of biomakers in oncology

Why test PD-L1?

PD-L1 expression is a potential biomarker, which has been studied in multiple tumour types in recent years.2

Knowing the expression level of PD-L1 in a tumour may provide additional evidence to support a physician when determining the appropriate therapeutic treatment strategy for individual patients.3,4 This knowledge may also facilitate discussions between the physician and patient on the potential benefits and risks of different treatment options.4

Professor Patrick Pauwels discusses the role of PD-L1 testing
for immunotherapy

Professor Marina Garassino discusses the role of PD-L1 testing
for immunotherapy

PD-L1 expression status adds to the dossier of information available to physicians for any individual patient when making a treatment decision.3–8

factors influencing treatment decisions

Dr Federico Cappuzzo discusses how PD-L1 testing can be useful for patients with NSCLC

Dr Federico Cappuzzo discusses the importance of obtaining all biomarker results before starting treatment for NSCLC


  1. Henry NL, Hayes DF. Mol Oncol 2012;6:140–46.
  2. Sun C, et al. Immunity 2018;48:434–52.
  3. Peters S, et al. Cancer Treat Rev 2018;62:39–49.
  4. Bellmunt J, et al. Cancer Treat Rev 2017;54:58–67.
  5. Sundar R, et al. Front Med 2017;4:39.
  6. Kelly CM, Shahrokni A. J Oncol 2016;2016:6186543.
  7. Kiebert GM, et al. Qual Life Res 1994;3:175–82.
  8. Maione P, et al. Rev Recent Clin Trials 2011;6:44–51.